drugset / Trial / NCT05491421
A Study of ZT002 in Healthy Participants
Phase 1
Completed
32 enrolled
QL Biopharmaceutical Australia Pty Ltd
Beijing QL Biopharmaceutical Co.,Ltd · collabNovotech (Australia) Pty Limited · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.
Timeline
- Start
- 2022-09-02
- Primary completion
- 2023-04-28
- Completion
- 2023-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZT002 | Peptide | 0.03 mg/kg | Subcutaneous |
| Subject | ZT002 | Peptide | 0.09 mg/kg | Subcutaneous |
| Subject | ZT002 | Peptide | 0.18 mg/kg | Subcutaneous |
| Subject | ZT002 | Peptide | 0.3 mg/kg | Subcutaneous |
| Subject | ZT002 | Peptide | 7 mg | Subcutaneous |
| Subject | ZT002 | Peptide | 10 mg | Subcutaneous |
| Subject | ZT002 | Peptide | 20 mg | Subcutaneous |
| Subject | ZT002 | Peptide | 40 mg | Subcutaneous |